Plenary: Targeted Radionuclide Therapy: What Every Oncologist Should Know

Radiopharmaceutical therapy (RPT) represents a rapidly expanding class of targeted cancer treatments that combine the precision of molecular targeting with the therapeutic potency of radionuclide delivery. Once confined to niche indications, RPT is now reshaping management strategies for common solid tumors such as prostate and neuroendocrine cancers—and a wave of next-generation agents targeting other malignancies is on the horizon. This foundational session provides oncologists with a clear, practical understanding of how radiopharmaceuticals work, where they fit in current practice, and how to integrate them into multidisciplinary solid tumor care. Faculty will outline approved therapies such as 177Lu-PSMA-617, 223Ra, and 177Lu-Dotatate, review patient selection and referral pathways, discuss safety and toxicity profiles, and highlight clinical opportunities and challenges. Attendees will gain the essential language, frameworks, and clinical cues needed to confidently navigate radiopharmaceutical therapy in daily practice and tumor board settings.